Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 in Relapsed/Refractory Extranodal NK/T Cell Lymphoma
NCT03363555Phase 2Unknown
- Sponsor
- Hengrui
- Start
- May 2018
- Primary completion
- Jun 2019
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Hengrui. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT03363555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03363555.